IP Library Granted Patent US 10,456,462
Granted Patent B2
US 10,456,462 · App. 15/742,249 · Granted Oct 29, 2019

Vaccine against RSV

Inventors: Johannes Langedijk (Amsterdam, NL); Dirk André Emmy Roymans (Turnhout, BE)
Assignee: Janssen Vaccines & Preventions B.V.
A61K39/155A61K39/12A61P31/14C07K14/005C07K2319/00C12N2760/18522C12N2760/18534
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,456,462
App. No.
15/742,249
Granted
Oct 29, 2019
Kind
B2
Abstract

Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.

Claims (13)

1. A composition comprising a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein the polypeptide comprises SEQ ID NO: 21.

2. A composition comprising a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide, wherein, as compared to a wild type RSV F polypeptide, the recombinant RSV F polypeptide comprises:

(i) a mutation of the amino acid at position 486 from aspartic acid (D) to asparagine (N), and

(ii) at least one of

a. a mutation of the amino acid residue at position 67 from asparagine (N) or threonine (T) to isoleucine (I), and

b. a mutation of the amino acid residue at position 215 from serine (S) to proline (P).

3. The composition of claim 2 , wherein the recombinant RSV F polypeptide comprises:

(i) the mutation of the amino acid at position 486 from aspartic acid (D) to asparagine (N),

(ii) the mutation of the amino acid residue at position 67 from asparagine (N) or threonine (T) to isoleucine (I), and

(iii) the mutation of the amino acid residue at position 215 from serine (S) to proline (P).

4. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 1 .

5. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 2 .

6. A method of inducing an immune response against RSV F protein in a subject in need thereof, the method comprising administering to the subject the composition according to claim 3 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: ROYMANS, DIRK ANDRE EMMY
To: JANSSEN INFECTIOUS DISEASES BVBA
Reel/Frame 044556/0631 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: JANSSEN INFECTIOUS DISEASES BVBA
To: CRUCELL HOLLAND B.V.
Reel/Frame 044556/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: LANGEDIJK, JOHANNES
To: CRUCELL HOLLAND B.V.
Reel/Frame 044556/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: LANGEDIJK, JOHANNES
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 044556/0762 →
CHANGE OF NAME Recorded Jan 8, 2018
From: CRUCELL HOLLAND B.V.
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 045016/0754 →
Priority Claims (1)
EP 15175647 · Jul 7, 2015 · regional
Continuity (1)
Related Publication 20180200360A1 · Jul 19, 2018
Cited By (3)
US 12,297,238 US 12,331,077 US 12,428,449